For Your Trading Desk
Trading Books

Price action, trading discipline, and the homework behind decisions made in seconds.

Click For Trade View

Sponsor Spike Success.

Scribe Therapeutics Stock Soars 67% Following $129 Million IPO

Jul 24, 2026
Scribe Therapeutics Stock Soars 67% Following $129 Million IPO

Scribe Therapeutics made a notable entrance on the , raising $128.7 million in its initial public offering and seeing its stock price increase by about 67% on the first day of trading. The company sold 8.58 million shares at $15 each, which was at the top end of its anticipated price range, under the ticker symbol SCTX. Founded between 2017 and 2018 from UC Berkeley’s Doudna Lab, Scribe Therapeutics is focused on CRISPR technology, specifically utilizing epigenetic silencing to regulate gene expression without permanently altering DNA.

The company's lead candidate, STX-1150, is currently undergoing Phase 1 clinical trials aimed at lowering LDL cholesterol levels. Additionally, Scribe is developing STX-1200, a preclinical program targeting lipoprotein(a) reduction, which has shown promising results in preclinical models with over 90% knockdown of Lp(a).

For Your Trading Desk
Trading Journals
Click For Trade View
Desk Accessories
Click For Trade View

Sponsor Spike Success.

Scribe's initial funding included a $20 million investment from Andreessen Horowitz, and by March 2026, the company reported a cash position of approximately $50 million. The firm has also secured partnerships with major pharmaceutical companies such as Biogen, Sanofi, and Eli Lilly, which provide milestone payments and potential royalties, allowing Scribe to generate revenue even before its products reach the market.

Initially, Scribe planned a smaller offering but expanded it to meet investor demand, ultimately landing at the sale of 8.58 million shares at $15 each. Despite the successful , Scribe remains a clinical-stage company, and with STX-1150 still in Phase 1 trials, there are years of testing, regulatory reviews, and potential challenges ahead before any revenue can be realized. purchasing shares at post-IPO prices are paying a premium compared to those who acquired shares at the initial offering price of $15.

For Your Trading Desk
Trading Books

Price action, trading discipline, and the homework behind decisions made in seconds.

Click For Trade View
Trading Journals

Log entries, exits, and the reason you clicked. 'It looked promising' deserves a second look.

Click For Trade View

Sponsor Spike Success.

Recommended for You
Anthropic Targets $2 Trillion Valuation in Upcoming Nasdaq IPO
Breaking Market News Oct 27, 2026

Anthropic Targets $2 Trillion Valuation in Upcoming Nasdaq IPO

Anthropic, known for its advanced AI model Claude, is set to make its debut on the Nasdaq under the ticker ANT. The company's IPO is…

For Your Trading Desk
Trading Books

Price action, trading discipline, and the homework behind decisions made in seconds.

Click For Trade View
Trading Journals

Log entries, exits, and the reason you clicked. 'It looked promising' deserves a second look.

Click For Trade View
Desk Accessories

Monitor stands and desk organizers for a trading setup with fewer loose ends.

Click For Trade View
Market Microstructure & Order Flow

Books on liquidity, order books, spreads, and trade execution. A closer look at what happens between clicking and getting filled.

Click For Trade View
Algorithmic Trading & Python

Coding and research books for systematic traders. Backtests deserve scrutiny, not a victory lap.

Click For Trade View
Financial Statements & Earnings Research

References for reading earnings reports, cash flow, and balance sheets. The headline rarely brings all the footnotes.

Click For Trade View

Sponsor Spike Success.

Across our publications

In Other News

Latest stories from other publications.

Explore all publications (opens in a new tab)